Clinical trial · Observational
RadioEmbolization for the ADvancement of Y90 Glass Microspheres Registry
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): due to Sponsor's ongoing and upcoming projects and overall research priorities
Summary
Brief summary (as posted)
This study is a non-interventional, observational, prospective, and global participant data registry. The study will collect effectiveness and safety data from approximately 1000 participants with liver cancers treated with TheraSphere® in a real-life setting from multiple centers globally. The absorbed dose to tumor and normal tissue will be calculated using the Simplicit90Y™ software in the subgroup of hepatocellular carcinoma (HCC) participants.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TheraSphere® | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Effectiveness of TheraSphere® treatment in participants with liver cancers in a real-life setting
- timeFrame
- 12 months follow up post last TheraSphere® treatment
- description
- Tumor response to TheraSphere® treatment will be assessed using Modified Response Evaluation Criteria in Solid Tumors (mRECIST) or Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 depending on tumor type.
Secondary outcomes (3)
- measure
- Serious adverse events
- timeFrame
- 6 months follow up post last TheraSphere® treatment
- description
- Serious adverse events assessed as related or possibly related to TheraSphere®.
- measure
- Adverse events of interest
- timeFrame
- 6 months follow up post last TheraSphere® treatment
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Participant is ≥ 18 years of age 2. Participant has confirmed liver cancer 3. Participant is able to provide informed consent according to local requirements/law 4. Participant has a life expectancy of ≥ 3 months 5. Participant is scheduled to receive TheraSphere® treatment Exclusion Criteria: 1. Participant who has previously received Y90 microspheres 2. Participant who has consented to participate in a BTG-sponsored clinical study that includes TheraSphere® treatment
References
Publications (0)
Data not yet available